The molecular action of Abeta oligomer on Alzheimer's disease.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25290018
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Nerve anatomy/Neuropathology
• Research Institution: Osaka City University
• Principal Investigator: MORI HIROSHI 大阪市立大学, 大学院医学研究科, 特任教授 (10159189)
• Co-Investigator(Kenkyū-buntansha): Tomiyama Takami 大阪市立大学, 大学院医学研究科, 准教授 (10305633) ; Umeda Tomohiro 大阪市立大学, 大学院医学研究科, 助教 (70549790)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 脳神経疾患 / 痴呆 / 老化 / アミロイド / オリゴマー

Outline of Final Research Achievements

We examined the most promising Abeta oligomer hypothesis　for therapeutic drug development of Alzheimer's disease. By additional introduction of human tau into an Abeta-oligomer mouse, we succeeded in making a new model to mimic Alzheimer's disease. Furthermore, we found an improvement effect with ability for space recognition or other pathological changes to rifampicin by the drug dosage experiment using the model. Hence, we believe that the Abeta oligomer is certificated with the new model, which are supposed to be suitable for future drug screening.

Free Research Field

認知症病態学